30 related articles for article (PubMed ID: 38704080)
1. Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.
Han Y; Wang Z; Sun S; Zhang Z; Liu J; Jin X; Wu P; Ji T; Ding W; Wang B; Gao Q
Epigenetics; 2020; 15(1-2):122-133. PubMed ID: 31423895
[TBL] [Abstract][Full Text] [Related]
2. DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma.
Luo X; Li N; Zhao X; Liao C; Ye R; Cheng C; Xu Z; Quan J; Liu J; Cao Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):300. PubMed ID: 31291971
[TBL] [Abstract][Full Text] [Related]
3. DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHKα to disrupt choline metabolism.
Li Z; Tan Y; Li X; Quan J; Bode AM; Cao Y; Luo X
Cell Death Dis; 2022 Oct; 13(10):845. PubMed ID: 36192391
[TBL] [Abstract][Full Text] [Related]
4. DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma.
Zhou Y; Wang L; Ban X; Zeng T; Zhu Y; Li M; Guan XY; Li Y
Oncogene; 2018 Feb; 37(8):1086-1094. PubMed ID: 29106393
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies.
Müller MR; Burmeister A; Skowron MA; Stephan A; Söhngen C; Wollnitzke P; Petzsch P; Alves Avelar LA; Kurz T; Köhrer K; Levkau B; Nettersheim D
Exp Cell Res; 2024 May; 439(1):114055. PubMed ID: 38704080
[TBL] [Abstract][Full Text] [Related]
6. Emerging roles of dehydrogenase/reductase member 2 (DHRS2) in the pathology of disease.
Li Z; Liu H; Bode A; Luo X
Eur J Pharmacol; 2021 May; 898():173972. PubMed ID: 33652058
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
Sharma NL; Groselj B; Hamdy FC; Kiltie AE
BJU Int; 2013 Apr; 111(4):537-42. PubMed ID: 23551441
[TBL] [Abstract][Full Text] [Related]
8. Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti R; Conte M; Altucci L
Antioxid Redox Signal; 2015 Jul; 23(1):99-126. PubMed ID: 24382114
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
[TBL] [Abstract][Full Text] [Related]
10. Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma.
Phimmachanh M; Han JZR; O'Donnell YEI; Latham SL; Croucher DR
Front Cell Dev Biol; 2020; 8():578770. PubMed ID: 33117806
[TBL] [Abstract][Full Text] [Related]
11. The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy.
Moran B; Davern M; Reynolds JV; Donlon NE; Lysaght J
Cancer Lett; 2023 Apr; 559():216121. PubMed ID: 36893893
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
